Efficacy and Safety of Calcipotriol / Betamethasone Dipropionate Topical Gel Used to Psoriasis Treatment

Psoriasis is the one of the most common skin disease. According to the reasearch Psoriasis disease is widely show in human at recent now, this is a long term disease it is triggered by the genetic issue, bad habit such as smoking, drinking, drug addiction etc. and some long term medication, insect bite etc. it can be affecting adult, child or old age people also. Now days latest research we have lot of option in drug or dosage form. In the topical dosage form GEL dosage form is the best option because of their application or improves patient compliance. It is big option for those drugs who had a problem with solubility with the dosage form. In the gel any drug can be easily incorporated. GEL can be easily applied or removed form skin by the single wash, their no extra afford need to rubbed on skin as compare other dosage form only just make single thin layer of skin. It also the problem with children dosing. Drug can be shows better effect on penetration on skin, and also increase bioavailability of drug. There is no adverse effect or using humectant cool the skin and relief form pain and itchy dry skin. While topical medications remain the cornerstone of the psoriasis treatment paradigm, they also come with the risk of multiple side effects. An alternative topical treatment option, calcipotriene or calcipotriol, is a vitamin D derivative that is thought to work by inhibiting keratinocyte proliferation and enhancing keratinocyte differentiation. Multiple studies have demonstrated its efficacy and safety in improving psoriasis when used in combination with topical corticosteroids. Given the effectiveness and side effect profile seen with this combination of topical steroid and calcipotriene, the US Food and Drug Administration approved a calcipotriene/ betamethasone dipropionate product for use in psoriasis patients over the age of 12 in 2006. Our paper seeks to review clinical trial evidence of this combination medication and its use in the treatment of psoriasis vulgaris. While assessment of available evidence indicates that the topical medication is both safe and effective for the treatment of psoriasis vulgaris, addressing limitations of what is known, such as tolerability, adherence, and patient preference, of this combination drug in future high-impact studies is needed. Combination topical corticosteroids and vitamin D analog treatments for nail psoriasis are widely used in cream and ointment vehicles, but patients may prefer a foam vehicle due to ease of application and favorable cosmetic appearance. Calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is an FDA approved therapy for plaque psoriasis, but may also be an effective treatment for nail psoriasis in a novel aerosol foam.